Enanta Pharmaceuticals Announces New Data Presentations at The Liver Meeting® 2016
- New pre-clinical data to be presented on Enanta’s FXR agonist EDP-305 for non-alcoholic steatohepatitis (NASH)
- Preliminary Phase 1 data to be presented on Enanta’s novel host-targeted cyclophilin inhibitor EDP-494 for hepatitis C virus (HCV) patients.
- New Phase 3 data to be presented on AbbVie’s investigational, pan-genotypic regimen for HCV consisting of glecaprevir (ABT-493), Enanta’s second protease inhibitor, in combination with pibrentasvir (ABT-530), AbbVie’s NS5A Inhibitor
New data investigating Enanta’s Farnesoid X Receptor (FXR) EDP-305, currently in Phase 1 development, will be presented demonstrating its potency, selectivity and effects on fibrosis progression and lipid metabolism in pre-clinical models. A new FXR preclinical lead compound with enhanced potency, EP-024297, will also be characterized. Also being presented will be single- and multiple-ascending dose data in healthy volunteers, as well as preliminary viral kinetic data in genotype 1 and genotype 3 HCV patients treated with EDP-494, Enanta’s novel host-targeted cyclophilin inhibitor.
In addition, several presentations will report late-stage clinical data in genotypes 1-6 from AbbVie’s chronic HCV clinical development program of regimens containing glecaprevir, (ABT-493), Enanta’s second HCV protease inhibitor, in combination with pibrentasvir, (ABT-530), AbbVie’s NS5A inhibitor. There will also be several presentations reporting data from AbbVie’s ongoing clinical development program for its marketed HCV treatment regimens containing Enanta’s first protease inhibitor, paritaprevir. Enanta’s protease inhibitors were identified through its collaboration with
Enanta and
Enanta Poster Presentations:
EDP-305 and EP-024297 FXR Agonists for Non-Alcoholic Steatohepatitis (NASH)
#650 - The Novel Farnesoid X Receptor (FXR) agonist, EDP-305, Reduces Fibrosis Progression in Bile Duct Ligated Rats
November 11 ,8:00 am to 5:30 pm ET - Session: Imaging and Non-invasive Markers of Liver Disease
- Author: C. Farrar, et al.
#1540 - EDP-305, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits High Potency and Efficacy In Vitro and In Vivo
November 13 ,8:00 am to 5:30 pm ET - Session: Steatohepatitis: Experimental I
- Author: Y. Li, et al.
#1568 - EDP-305, A Novel and Highly Potent Farnesoid X Receptor Agonist, Exerts Favorable Effects on Lipid Metabolism In Vitro
November 13 ,8:00 am to 5:30 pm ET - Session: Steatohepatitis: Experimental II
- Author: Y. Li, et al.
#1569 - EP-024297, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits High Potency and Efficacy In Vitro and In Vivo
November 13 ,8:00 am to 5:30 pm ET - Session: Steatohepatitis: Experimental II
- Author: M. Chau, et al.
#1596 - EDP-305, A Novel and Potent Farnesoid X Receptor Agonist, Exhibits Favorable Anti-inflammatory and Anti-fibrotic Activity In Vitro
November 13 ,8:00 am to 5:30 pm ET - Session: Steatohepatitis: Experimental II
- Author: Y. Li, et al.
EDP-494, Cyclophilin Inhibitor for HCV
#1453 - Safety, Tolerability, Pharmacokinetics (PK) and Antiviral Activity of EDP-494, a Potent Pan-Genotypic Cyclophilin (Cyp) Inhibitor for Chronic Hepatitis C Infection (CHC), in Healthy Subjects (HS) and in CHC Genotype 1 and 3 Patients: Preliminary Results
•
- Session: HCV Therapeutics: Preclinical and
Early Development - Author: E. Gane, et al.
AbbVie Presentations Regarding glecaprevir (ABT-493) for HCV:
Oral Presentations:
#73 – ENDURANCE 2: Safety and Efficacy of ABT-493/ABT-530 in Hepatitis C Virus Genotype 2-infected Patients without Cirrhosis, a Randomized, Double-Blind, Placebo-Controlled Study
November 13 , Parallel E (Session 6-13); Parallel 11: Hepatitis C: New and Existing Agents- Time:
3:00 to 4:30 pm ET - Author: K. Kowdley, et al.
#113 – SURVEYOR II, Part 3: Efficacy and Safety of ABT-493/ABT-530 in Patients with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience and/or Cirrhosis
November 13 , Parallel F, (Sessions 14-20); Parallel 17: Hepatitis C: Phase 2/3 Trials- Time:
4:45 to 6:15 pm ET - Author: D. Wyles, et al.
#114 – ENDURANCE 4: Efficacy and Safety of ABT-493/ ABT-530 Treatment in Patients with Chronic HCV Genotype 4, 5, or 6 Infection
November 13 , Parallel F (Sessions 14 – 20); Parallel 17: Hepatitis C: Phase 2/3 Trials- Time:
4:45 to 6:15 pm ET - Author: T. Asselah, et al.
#253 – ENDURANCE 1: Efficacy and Safety of 8- versus 12-week Treatment with ABT-493/ABT-530 in patients with Chronic HCV Genotype 1 Infection
November 15 , Viral Hepatitis Plenary Session- Time:
9:30 to 11:00 am ET - Author: S. Zeuzem, et al.
Poster Presentations Regarding glecaprevir (ABT-493):
#849 – Analysis of HCV Variants in the MAGELLAN-1 Part 1 Study: ABT-493 and ABT-530 Combination Therapy of Genotype 1-Infected Patients Who Had Failed Prior Direct Acting Antiviral-Containing Regimens
November 12 , Poster Session II- Time:
5:30 to 7:30 pm ET - Author: T. Ng, et al.
#854 – Drug-drug Interactions between Direct Acting Antivirals ABT-493 and ABT-530 with Angiotensin II Receptor Blockers (losartan or valsartan)
November 12 , Poster Session II- Time:
5:30 to 7:30 pm ET - Author: M Kosloski, et al.
#855 – Hemodialysis Does Not Affect the Pharmacokinetics of ABT‐493 or ABT‐530
November 12 , Poster Session II- Time:
5:30 to 7:30 pm ET - Author: M Kosloski, et al.
About Enanta
Enanta has discovered novel protease inhibitors and NS5A inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). Enanta’s protease inhibitors, developed through its collaboration with
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including statements with respect to the prospects for AbbVie’s investigational HCV treatment regimen containing glecaprevir (ABT-493) and the prospects for Enanta’s further development of EDP-494, EDP-305 other FXR agonists. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the efforts of
View source version on businesswire.com: http://www.businesswire.com/news/home/20161003005798/en/
Source:
Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media Contact
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR